Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 4, Room B1-28, 4 Memorial Drive, Bethesda, MD 20892, USA.
National Capital Consortium Allergy & Immunology ellowship, Department of Medicine, Allergy & Immunology Service, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Immunol Allergy Clin North Am. 2024 Nov;44(4):629-644. doi: 10.1016/j.iac.2024.07.003. Epub 2024 Aug 16.
Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) are complex disorders defined by blood and tissue eosinophilia and heterogeneous clinical manifestations. Historically, the mainstay of therapy for both conditions has been systemic glucocorticoids. However, recent availability of biologics that directly or indirectly target eosinophils has provided new avenues to pursue improved outcomes with decreased toxicity. In this article, we summarize the evidence supporting the use of specific biologics in HES and/or EGPA and provide a framework for their clinical use in patients.
嗜酸性粒细胞增多综合征（HES）和嗜酸性粒细胞性肉芽肿伴多血管炎（EGPA）是由血液和组织嗜酸性粒细胞增多以及异质性临床表现定义的复杂疾病。历史上，这两种疾病的主要治疗方法都是全身性糖皮质激素。然而，最近可直接或间接靶向嗜酸性粒细胞的生物制剂的出现，为降低毒性的同时改善预后提供了新的途径。本文总结了支持在 HES 和/或 EGPA 中使用特定生物制剂的证据，并为其在患者中的临床应用提供了框架。
